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The Crystal Structure of Human CDK7
and Its Protein Recognition Properties
ylation has not been identified, but in vitro active phos-
pho-CDK2/cyclin A will promote phosphorylation and
CDK7/cyclin H assembly (Fisher et al., 1995).
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Department of Biochemistry CDK7 also plays a central role in the regulation of the
initiation phase of messenger RNA synthesis by RNAUniversity of Oxford
Rex Richards Building pol II. CDK7 is part of the general transcription factor
TFIIH (Feaver et al., 1994; Roy et al., 1994; SchiekhattarOxford, OX1 3QU
United Kingdom et al., 1995; Serizawa et al., 1995) and in this complex
phosphorylates RNA polymerase II (RNA pol II) large
subunit C-terminal domain (CTD) (Goodrich and Tjian,
1994; Lu et al., 1992; Oelgeschlager, 2002; PalancadeSummary
and Bensaude, 2003; Shilatifard et al., 2003). The CTD
contains a tandem array of 52 repeats (in humans) withCDK7, a member of the cyclin-dependent protein ki-
the consensus sequence YSPTSPS (using the singlenase family, regulates the activities of other CDKs
letter code). CDK7 preferentially phosphorylates Ser5 inthrough phosphorylation on their activation segment
this sequence. Phosphorylation of the CTD facilitatesand hence contributes to control of the eukaryotic cell
promoter clearance, initiation of transcription (Dahmus,cycle. CDK7 also assists in the regulation of transcrip-
1996), and recognition by RNA processing enzymes.tion as part of the transcription factor TFIIH complex.
In order to form a stable dimeric active complex withFor maximum activity and stability, CDK7 requires
cyclin H, CDK7 must be phosphorylated on a conservedphosphorylation, association with cyclin H, and asso-
threonine (T170 in the human protein) in the activationciation with a third protein, MAT1. We have determined
loop (Fisher et al., 1995; Martinez et al., 1997). Unlikethe crystal structure of human CDK7 in complex with
other CDKs, CDK7 has an additional phosphorylationATP at 3 A˚ resolution. The kinase is in the inactive
site in the activation segment (Ser164 in the human pro-conformation, similar to that observed for inactive
tein). Phosphorylation at this site enhances activity andCDK2. The activation segment is phosphorylated at
cyclin binding (Martinez et al., 1997). The trimeric CDK7/Thr170 and is in a defined conformation that differs
cyclin H/MAT1 complex is active in the absence of phos-from that in phospho-CDK2 and phospho-CDK2/cyclin
phorylation but phosphorylation stabilizes the complexA. The functional properties of the enzyme against
and stimulates activity toward the CTD of RNA Pol IICDK2 and CTD as substrates are characterized through
without affecting activity on CDK2 (Larochelle et al.,kinase assays. Experiments confirm that CDK7 is not
2001). Additional factors also regulate CDK7 substratea substrate for kinase-associated phosphatase.
selectivity in TFIIH (Akoulitchev et al., 2000; Akoulitchev
and Reinberg, 1998; Chen et al., 2003; Nishiwaki et al.,
Introduction 2000; Serizawa, 1998).
Unlike other cell cycle CDKs, cyclin H levels and CDK7
The cyclin-dependent protein kinase 7 (CDK7) plays key activity do not vary throughout the cell cycle. For several
roles in the regulation of the eukaryotic cell cycle and CDKs, the phosphatases PP2C (Cheng et al., 2000) and
in the control of transcription. These dual roles are in the kinase-associated phosphatase (KAP) (Poon and
turn regulated by the phosphorylation state of the en- Hunter, 1995) have been identified that recognize
zyme and the association with regulatory subunits. Like and dephosphorylate the phospho site on the activation
most other CDKs, CDK7 requires association with an segment leading to inactive CDK. The crystal structure
activatory cyclin, cyclin H, and phosphorylation on the of KAP in complex with phospho-CDK2 (pCDK2) (Song
activation loop for activity. Assembly and activity are et al., 2001) showed that the major protein interface
augmented by a third protein, the RING finger protein between the two proteins is formed by the C-terminal
MAT1 (Devault et al., 1995; Fisher et al., 1995; Tassan helix of KAP and the C-terminal lobe of CDK2, regions
et al., 1995). CDK7 CDK activation (CAK) activity is es- that are remote from both the KAP catalytic site and
sential for cell cycle progression in vivo (Harper and the activation segment carrying the pThr160 residue of
Elledge, 1998; Larochelle et al., 1998; Wallenfang and CDK2. At the KAP catalytic site, the CDK2 activation
Seydoux, 2002). segment interacted almost entirely through the phospho
CDK7/cyclin H or CDK7/cyclin H/MAT1 will phosphor- group and the structure required a movement of the
ylate CDK1, CDK2, CDK4, CDK5, and CDK6 (Kaldis et activation segment in which it became unfolded and
al., 1998; Rosales et al., 2003; Solomon et al., 1992) on drawn away from the kinase. Sequence comparisons
their respective threonines in the activation segment showed that the KAP remote recognition site on CDK2
leading to activation of these kinases. Levels of CDK7 was not conserved in CDK7 and suggested that CDK7
in cells are low (Fisher and Morgan, 1994) and CDK7 would not be a substrate for KAP.
location is predominantly nuclear (Tassan et al., 1994). As a first step toward understanding the recognition
The in vivo activating kinase for human CDK7 phosphor- properties of CDK7, we report the crystal structure of
CDK7 phosphorylated on Thr170 and in complex with
ATP. The kinase is in an inactive conformation similar*Correspondence: louise.johnson@biop.ox.ac.uk
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Table 1. Summary of CDK7 Data Collection and Refinement Statistics
3.3 A˚, ID29 3.0 A˚, ID13 Combined Data
Space group and unit cell (A˚) P21: a  66.33, b  193.18, P21: a  65.50, b  191.63,
c  77.42,   95.12 c  75.79,   94.40
Resolution range (A˚) (last shell) 23.3–3.3 (3.48–3.3) 30.0–3.0 (3.16–3.0) 30.0–3.0 (3.16–3.0)
Rsym 0.105 (0.225) 0.165 (0.493) 0.143 (0.569)
Observations 90970 (12322) 54240 (7970) 147115 (8046)
Unique observations 28078 (4102) 29716 (4471) 36804 (4531)
Mean(I)/(I) 10.4 (4.8) 6.1 (1.5) 8.5 (1.2)
Completeness 96.4 (96.5) 80.0 (82.3) 94.9 (80.3)
Multiplicity 3.2 (3.0) 1.8 (1.8) 4.0 (1.8)
Refinement statistics
Rfactor 0.219
Rfree 0.296
Rmsd bond lengths (A˚) 0.017
Rmsd bond angles () 1.970
to that of inactive CDK2 but the activation segments of The results from CDK7 mass spectrometry show two
peaks with molecular mass of 39,217 and 39,141 corre-the two CDKs differ. We describe the similarities and
differences between CDK7 and CDK2 and other protein sponding to approximately 30% bisphosphorylated
CDK7 (39,061  160) and 70% monophosphorylatedkinases with respect to their ATP binding sites and their
protein recognition sites, including that for KAP. We CDK7 (39,061  80). The results were identical for two
separate preparations. In the crystal structure, we findcorrelate the structural observations with kinase activity
measurements. only the monophosphorylated form. Thr170 is phosphor-
ylated and Ser164 is not phosphorylated (Figure 1B).
The pThr170 makes one hydrogen bond through itsResults
phosphate group to the main chain nitrogen of Gln22
from the glycine loop between 1/2 and is otherwiseThe Structure of CDK7
The structure of CDK7 was solved by molecular replace- exposed to the solvent (Figure 1C). The phospho-threo-
nine approaches the  phosphate of ATP (the distancement using the structure of inactive CDK2 as a search
object (Table 1). The CDK7 structure exhibits a typical between the  phosphorous of ATP and the phospho-
threonine phosphorus atoms is 6.7 A˚), but the side chainkinase fold comprising the N-terminal lobe (residues
13–96), with mostly  sheet and one  helix (C), and a of Gln22 partly intervenes between the two phosphates.
The structure suggests that autophosphorylation onC-terminal lobe (residues 97–311) comprised mostly of
 helices (Figure 1A). The fold can be traced from residue Thr170 is unlikely in agreement with results in solution
(Martinez et al., 1997; Poon et al., 1994). Ser164 is ex-13 to 311 in the 3.0 A˚ resolution electron density, whose
quality is enhanced by the 4-fold noncrystallographic posed on the surface of the protein. There is no addi-
tional density surrounding this side chain to indicatesymmetry averaging. There is one break between resi-
dues 44–55, corresponding to the link between the 3 phosphorylation (Figure 1B). Ser164 is contained in a
consensus sequence for CDK2 phosphorylation (SPNRstrand and the C helix. The N-terminal residues 1–12
and the C-terminal residues 312–346, that contain a pu- in single letter code) but has not been 100% phosphory-
lated in insect cells.tative nuclear localization sequence, are not located in
the electron density. ATP is bound between the two
lobes and was clearly identifiable in all four copies of Comparison of CDK7 and CDK2 Structures
The structures of CDK7 and CDK2 are similar with anthe CDK7 structure. The conformation of CDK7 is similar
to the inactive conformation of CDK2 in the absence rms deviation in C positions for 251 residues of 1.25 A˚.
CDK7 has 44% sequence identity to CDK2 (Figure 2).of cyclin A (De Bondt et al., 1993). The C-helix, which
contains the sequence NRTALRE (residues 56–62) in Major changes between CDK7 and CDK2 occur in three
regions: (i) the activation segment (CDK7 residues 155–CDK7 corresponding to the PSTAIRE sequence motif in
CDK2, is rotated about its axis and shifted toward the 174); (ii) the region where three parts of chain pack
together comprising D (CDK7 residues 101–112), theexterior of the protein compared with its conformation
in the active CDK2/cyclin A complex (Jeffrey et al., 1995; 7/8 loop (CDK7 residues 146–149), and the C-terminal
region (CDK7 residues 297–311); and (iii) the region ofRusso et al., 1996a). All side chains in the region 56–62
(NRTALRE) are exposed. As a result, the interaction be- the L14 loop (residues 247-251) which is part of the KAP
recognition site and Cks1 regulatory protein binding sitetween the glutamate from the C helix (Glu62) and a lysine
(Lys41), which stabilizes the lysine residue for interac- in CDK2 (Figure 3A). Changes in these regions have
possible functional significance. In addition there aretion with the triphosphate of ATP in active protein ki-
nases, is not made. The activation segment (Johnson also smaller changes at the N-terminal region and in the
loop regions between 1/2, 2/3 and 4/5 (Fig-et al., 1996) is well localized in the electron density but
has higher B factors than the rest of the molecule (aver- ure 3A).
The activation segment of CDK7 adopts a differentage B factors for main chain atoms for chain A: 42 A˚2;
average main chain B factors for activation segment conformation to that observed for CDK2 and phospho-
CDK2 (pCDK2) (Figure 3B). In pCDK2 (CDK2 phosphory-residues 155-182 in chain A: 58 A˚2).
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Figure 1. The Structure of CDK7/ATP Com-
plex
(A) A schematic diagram of CDK7 with sec-
ondary structural elements labeled. ATP is
bound between the N- and C-terminal lobes.
There is a break in electron density between
the end of 3 and the start of C. The activa-
tion segment is in a darker color.
(B) The activation segment is phosphorylated
on Thr170 and not on Ser164. The final Sig-
maA weighted 2Fo  Fc electron density map
contoured at 0.94 for residues 164–172.
(C) The activation segment of CDK7 in resi-
dues 163–171 showing the contacts of the
pThr170 with the main chain nitrogen of Gln22
from the glycine loop between 1/2. This
diagram and other figures were produced
with AESOP (M.E.M. Noble, personal commu-
nication).
lated on T160 but without the association of cyclin A) phosphorylation, the activation segment of CDK2 under-
goes a dramatic change in conformation (Figure 3B).(Brown et al., 1999b) the structure is similar to inactive
nonphospho CDK2 with the only difference that the acti- The separation of C pThr170 (CDK7) to C pThr160 in
pCDK2/cyclin A is 23.7 A˚.vation segment is disordered. In CDK7, at the start of
the activation segment, the side chain of aspartate The second major change is at the C terminus where
residues 297–309 in CDK7 differ from the correspondingAsp155 of the DFG motif is turned away from the cata-
lytic site forming a hydrogen bond with Lys41, in a similar residues in CDK2. The CDK7 proline-rich C-terminal re-
gion makes more intimate contacts with the rest of theconformation to that observed for inactive CDK2. In this
position the aspartate is unable to participate in con- protein than with the corresponding region in CDK2. The
interactions involve the end of D and the D/E looptacts to the magnesium ion that interacts with the  and
 phosphates of ATP in the activated form of CDKs. (residues 101–112, a region where there is little similarity
in sequence between CDK7 and CDK2), and the regionCDK7 and inactive CDK2 activation segments differ from
this point (Asp155 in CDK7, Asp145 in CDK2) until they of the 7/8 loop residues146–149 (Figure 3A). The
C-terminal region threads between these two loops andcome back into register at residue Arg176 in CDK7
(Leu166 in CDK2) corresponding to the middle of the appears to displace the 7/8 loop. The end of the hinge
region at 6 is also displaced and the D helix in CDK7P  1 loop. As in CDK2, there is a short two-turn helix
(residues 158–165), which docks against the C helix lacks the final turn as seen in CDK2. The shifts allow
favorable contacts: for example, Pro308 interacts withkeeping the latter in the inactive conformation through
interactions such as the packing of Phe156 against Val108 (D/E loop), Arg309 ion pairs with Glu147 (7/8
loop), and Pro310 near the C terminus interacts withVal65. The activation segment takes a more open route
in CDK7 than in CDK2 (Figure 3B), resulting in the dis- Val100 and Ile101 (D helix).
Protein kinases contain several protein interactingtance of 3.8 A˚ between C atoms of pThr170 (CDK7)
and Thr160 (CDK2). On association with cyclin A and sites on their surfaces. The MAP kinase family members
Structure
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Figure 2. Sequence Alignment of CDK7 and
CDK2 Showing the Assignment of Secondary
Structural Elements in CDK7
Beta strands are shown as arrows and  heli-
ces as shaded boxes. Short stretches of 
helix or 310 helix are shown as open boxes.
interact specifically with docking site sequences in sub- 5A). The differences arise from the overall differences
strates (Sharrocks et al., 2000). These interactions may in protein conformation, partly promoted by the differ-
confer pathway specificity and substrate selection and ence in conformation of the activation segments, and
provide an additional recognition site that is separate the lack of magnesium ions in the CDK7 structure.
from the catalytic substrate recognition site. The struc- Overall, the number of van der Waals contacts made
ture of p38 in complex with docking peptides from two between ATP and CDK7 and between ATP and the inac-
such interacting proteins, one from a transcription factor tive form of CDK2 are similar but the residues involved
MEF2A and the other from an activating kinase MKK3b are different. ATP in CDK7 makes more extensive con-
(Chang et al., 2002), show these peptides interacting at a tacts to the glycine loop than in CDK2 but fewer contacts
site that is equivalent to that occupied by the C-terminal to the catalytic residues and the metal binding residues.
region of CDK7 (i.e., the pocket between 7/8 loop and The adenine of ATP makes two hydrogen bonds to the
the D/E loop [Figure 3C]). In particular in CDK7 proline hinge region between the two lobes, as observed in
residues 308 and 310 occupy the equivalent positions other kinase structures, and also contacts the hinge
to the nonpolar residues in the sequence φa-X-φb that region residue Met94 (Figure 5B). The ribose in CDK7
is the hallmark of these p38-docking peptides. Although is closer toward the glycine loop than in CDK2, while
the C-terminal region of CDK2 also occupies this pocket, the triphosphate moieties are very different especially
the nonpolar interactions are not manifest to such a for the  phosphates. In CDK7 two of the  phosphate
dramatic extent as in CDK7.
oxygens hydrogen bond to main chain nitrogens of
The third region of major difference is in the CDK
Phe23 and Ala24 at the 1/2 turn making a well-local-insert region L14 where there is a deletion of one residue
ized arrangement with the glycine loop. A third  phos-in CDK7 with respect to CDK2 (Figures 2 and 3A). This
phate oxygen hydrogen bonds to Lys41. The differenceregion forms part of the recognition site of pCDK2 for
in conformation of the activation segment betweenbinding KAP (Song et al., 2001) (Figure 4A). In the
CDK7 and CDK2 allows the side chain of Ser161 topCDK2/KAP complex, Lys237 of CDK2 makes an ion
contribute a hydrogen bond to the  phosphate in CDK7.pair with Glu191 of KAP (Figure 4B). In CDK7, the corre-
This residue occupies the position of Tyr15 in CDK2sponding residue to Lys237 is Val247 (Figure 4C). The
reflecting differences in the activation segments andsmall changes in sequence and conformation of this
glycine loops. In CDK7 Phe162, near the start of theregion suggest that KAP would not be able to recognize
activation segment, stacks against Phe23, the residuepCDK7 and would not be able to dephosphorylate
corresponding to Tyr15 in CDK2. The absence of metalCDK7. This hypothesis is further explored below.
ion in the CDK7 structure appears to have encouraged
the  phosphate to seek hydrogen bonds with the gly-The ATP Binding Site
cine-loop main chain nitrogens rather than with the cata-ATP bound to CDK7 has a slightly different conformation
and contacts than those of ATP bound to CDK2 (Figure lytic residues.
Crystal Structure of Human CDK7
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Figure 3. Comparison of the Structures of CDK7 and CDK2
(A) A schematic diagram of CDK7 (in brown) and CDK2 (in cyan). There are significant changes in three major regions: the activation segment;
the C-terminal region and contacts to the 7/8 loop and the end of the D helix; and the L14 loop, the site of interaction of KAP in CDK2.
(B) Comparison of the activation segments from CDK7 (brown), CDK2 (cyan), and activated pCDK2/cyclin A (green). The region from 155
(CDK7) DFG to 182 (CDK7) APE is shown.
(C) The C-terminal region of CDK7 (brown) with the p38 structure (green) (PDB ID 1LEW) superimposed. The binding of the MEF2A docking
peptide to p38 is shown in magenta. This overlaps the C-terminal region of CDK7.
Kinase Assays and Substrate Specificity factor 2.5 (Figure 6A, lane 2, and Figure 6B) in agree-
ment with (Watanabe et al., 2000). The trimeric CDK7/In order to determine the activation state of the crystal-
line CDK7 and to probe the influence of cyclin H and cyclin H/MAT228 complex is more active against the
CTD substrate than against CDK2 (Figure 6A, lane 3,MAT1 on activity and specificity, we compared the rela-
tive activities of CDK7, CDK7/cyclin H, and CDK7/cyclin and Figure 6B). Under our conditions, CTD phosphoryla-
tion is increased by 4 times over that observed forH/MAT228 against CDK2 and CTD as substrates.
MAT228 (residues 228–309) is the minimal region of CDK7/cyclin H while the CDK2 CAK activity is not signifi-
cantly affected by the presence of MAT228.MAT1 that is able to stimulate CDK7/cyclin H activity
(Busso et al., 2000). In the presence of ATP, both CDK7/cyclin H and
CDK7/cyclin H/MAT228 will autophosphorylate cyclin HCDK7 has no activity against CDK2 but does have a
weak basal activity against the CTD (Figure 6A, lane 1 (unpublished data). Phosphorylation of cyclin H results
in a reduction in the activity of the dimeric CDK7/cyclinand Figure 6B). CDK7/cyclin H complex is active with
greater activity against CDK2 than against CTD by a H complex against both CDK2 and CTD (Figure 6C)
Structure
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Figure 4. Comparison of the KAP Binding Site between pCDK2 and pCDK7
(A) Overall schematic diagram with CDK7 (brown) superimposed on the pCDK2/KAP complex (pCDK2 is in cyan and KAP in blue).
(B) Details of the pCDK2/KAP binding site. pCDK2 is in cyan and KAP in magenta. There is an ionic interaction between Lys237 (pCDK2) and
Glu191 (KAP).
(C) Details of the changes at this site in CDK7 (in gold) with the key KAP residues superimposed. Val247 (which replaces Lys237 of CDK2)
cannot interact favorably with Glu191. For further details see text.
but no change in activity of the trimeric CDK7/cyclin CDK7/cyclin H or CDK7/cyclin H/MAT228 complexes
produced by coinfection in insect cells, were found byH/MAT228 complex against either CDK2 or CTD (Figure
6C). It is possible that cyclin H phosphorylation destabi- mass spectrometry to have CDK7 60% bisphosphory-
lated and 40% monophosphorylated (data not shown).lizes the dimeric complex (thus reducing its activity), but
the presence of MAT1 provides additional stability in To analyze the influence of CDK7 phosphorylation state
on activity, we compared the CDK2 CAK activities beforethe trimeric complex and thus is able to counteract the
effects of phosphorylation of cyclin H. Thus, MAT1 may and after incubation with pThr160-CDK2/cyclin A and
ATP (Figure 6D). The CDK2 reaction appears to go tohave an additional role in regulating CDK7 activity by
allowing the activity to escape regulation by cyclin H completion because subsequent incubations of these
preparations with pCDK2/cyclin A and ATP led to nophosphorylation.
Crystal Structure of Human CDK7
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CDK7/cyclin H and CDK7/cyclin H/MAT228 complexes
(Figure 6D). There is an increase in activity of 2.8 and
3.7 times for the additionally phosphorylated CDK7/
cyclin H and CDK7/cyclin H/MAT228 complexes, re-
spectively. The lower activity of pCDK7/cyclin H with
respect to pCDK7/cyclin H/MAT228 can most likely be
ascribed to the autophosphorylation on cyclin H (de-
scribed above) that causes a 35% reduction in activity
of CDK7/cyclin H but no reduction for CDK7/cyclin
H/MAT228 (Figure 6C). Activity against the CTD could
not be tested under these conditions because pThr160-
CDK2/cyclin A also phosphorylates CTD (Palancade and
Bensaude, 2003).
KAP Dephosphorylates CDK2 but Not CDK7
The structure of the complex between KAP and pCDK2
(Song et al., 2001) showed that recognition at the cata-
lytic site was achieved solely through the phosphate
group but that the major determinant of specificity was
located about 20 A˚ from the catalytic site where the
C-terminal helix of KAP interacted with residues from
the G helix and the L14 loop of CDK2. The L14 region
differs in CDK7 (Figure 4) resulting from sequence
changes that involve the sequence DYV(247)-T in CDK7
(where – denotes a gap) and DYK(237)PS in CDK2 (Fig-
ure 2). In order to test if these features destroy the
docking site and abolish KAP activity, we tested KAP
activity against CDK7 and constructed KAP-interacting
mutants (KM) for CDK2 and CDK7. KM-CDK2 has the
sequence Val237- in place of Lys237Pro238; KM-CDK7
has the sequence Lys247Pro in place of Val247-. These
mutations create two chimeras: CDK2 with CDK7-L14
loop and CDK7 with CDK2-L14 loop.
The profile of KAP activity against pThr160-CDK2,
KM-pCDK2, CDK7, and KM-CDK7 is showed in Figure
7A. As expected, KAP is active against pCDK2 and inac-
tive against CDK7. Dephosphorylation of pCDK2 results
in a band shift in which dephosphorylated CDK2 mi-
grates slower than the phosphorylated isoform (Figure
7A, lanes 2 and 1, respectively). No bandshifts can be
detected after KAP treatment of CDK7 either for theFigure 5. Comparison of pCDK7/ATP and CDK2/ATP Interactions
monophosphorylated (upper band) or bisphosphory-(A) Comparison of ATP bound to CDK7 (carbon atoms in green) and
lated (lower band) forms of CDK7 (Figure 7A, lanes 5ATP bound to CDK2 (carbon atoms in yellow).
(B) Details of the interactions between CDK7 and ATP. and 6). The L14 loop mutations in KM-pCDK2 abolish
(C) Details of the interactions between CDK2 and ATP. For further KAP activity (no bandshift detectable: Figure 7A, lanes
details see text. 3 and 4). This result highlights the importance of the
docking site for the regulation of KAP activity on pCDK2.
However, KAP is not active against KM-CDK7 (Figurefurther incorporation of phosphate and the phospho-
CDK7 ran as a single band under gel electrophoresis in 7A, lanes 7 and 8). Evidently the generation of a correct
KAP docking site on CDK7 was not sufficient to makecontrast to the two bands seen when both bis- and
mono-phospho forms were present. After preincubation it a substrate. This may be because other effects are
also important. For example, the rigidity of the pCDK7with pThr160-CDK2/cyclin A CDK7 showed weak activ-
ity, quantifiable as approximately 2% of the CDK7/cyclin activation segment compared with the disordered acti-
vation segment in pCDK2 may make it less amenableH activity. Martinez et al. (1997) found that Xenopus
CDK7 and CDK7/cyclin H can be activated by CDK2/ for conformational change to reach the KAP catalytic
site. We note that the relative intensity of the bands incyclin A or CDK1/cyclin B in reticulocyte-translated ly-
sates with pCDK7 achieving approximately one-third of Figure 7, show that KM-CDK7 is approximately 70%
bisphosphorylated and 30% monophosphorylated (Fig-the activity of the CDK7/cyclin H complex. From our
results, we conclude that in human phospho-CDK7, in ure 7A, lane 7), while CDK7 is 30% bisphosphorylated
and 70% monophosphorylated (Figure 7A, lane 5).contrast to Xenopus CDK7, does not exhibit appreciable
CDK2 CAK activity. In order to verify that these mutations did not affect
the overall folding and the other binding sites of CDK2The effects of phosphorylation are more evident in the
Structure
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Figure 6. Kinase Activities of CDK7, CDK7/
Cyclin H, and CDK7/Cyclin H/MAT228
(A) Autoradiograph of CDK2 and CTD phos-
phorylated by CDK7 (lane 1), CDK7/cyclin H
(lane 2), and CDK7/cyclin H/MAT228 (lane 3).
The reactions were performed as described
in Experimental Procedures.
(B) Relative CDK2 and CTD phosphorylation
activities for CDK7 CDK7/cyclin H and CDK7/
cyclin H/MAT228 from results shown in (A).
Cyclin H in the dimeric complex generates
CAK activity on CDK2 making CDK2 the pre-
ferred substrate for CDK7. MAT228 in the tri-
meric complex increases CTD phosphoryla-
tion without affecting CAK activity.
(C) Autophosphorylation on cyclin H de-
creases CDK7/cyclin H activities on CDK2
and CTD without affecting CDK7/cyclin H/
MAT228 activities.
(D) Effect of CDK7 phosphorylation by
pThr160-CDK2/cyclin A on CAK activity. Min-
imal basal activity is induced in CDK7 (change
too small to be observed in this figure). CDK7/
cyclin H and CDK7/cyclin H/MAT228 com-
plexes showed an increase in activity of2.8
and 3.7 times after preincubation with
pThr160-CDK2/cyclin A.
and CDK7, we compared activity of wild-type and mu- crystallization showed no activity against CDK2 but did
exhibit basal activity against the CTD from RNA polymer-tant proteins (Figure 7B). Phosphorylation of CDK7 by
ase. The lack of conventional activity against CDK2 ispThr160CDK2 or KM-pThr160CDK2 are similar (Figure
consistent with the inactive conformation of the kinase7B, lanes 1 and 2) and the activatory effects of cyclin A
observed in the crystal structure. Further phosphoryla-on pCDK2 or KM-pCDK2 for phosphorylation of CDK7
tion of CDK7 by pCDK2/cyclin A in order to achieve fullare also similar (Figure 7B, lanes 3 and 4). These results
phosphorylation on both Thr170 and Ser164, led to noshow that KM-pCDK2 has been phosphorylated by Civ-1
significant CAK activity against CDK2. Phosphorylationduring expression to give the active enzyme and that
of the activation segment in CDK7 is insufficient to trig-mutation of pCDK2 L14 loop does not affect interactions
ger the conformational changes that convert an inactivewith either cyclin A or with the substrate CDK7. Both
kinase to an active kinase.CDK7 and KM-CDK7 are able to phosphorylate CTD
Association of CDK7 with cyclin H and with cyclin(Figure 7B, lanes 5 and 6). The higher activity of KM-
H/MAT228 leads to significant activity against bothCDK7 is ascribed to its different phosphorylation state
CDK2 and the CTD. In these complexes there is a higherin respect to CDK7 (described above). We conclude
amount of bisphosphorylated CDK7 than monophosph-that mutation of CDK7 L14 loop does not affect activity
orylated CDK7 (ratio 60:40) produced by the insect cells.against the CTD.
We find that the CDK7/cyclin H complex has a prefer-
ence for CDK2 over CTD of about 2.5-fold at substrate
Discussion concentrations of 7.6 	M, as others have also observed
(Watanabe et al., 2000) but that with the CDK7/cyclin
The crystal structure of CDK7 shows that the overall H/MAT228 complex the substrate preference is shifted
fold of the kinase is similar to that of inactive CDK2, as by a ratio of about 1.4 in favor of the CTD. Others have
expected from their sequence similarity. Major differ- observed a more dramatic shift in substrate specificity
ences occur in the activation segment, the C-terminal on association with MAT1 (Larochelle et al., 1998; Yan-
region and the L14 loop, which is part of the CDK2 kulov and Bentley, 1997). The MAT1 construct of resi-
recognition site for KAP. Mass spectrometry indicated dues 228-309, which was used in our experiments, has
a 30:70 ratio of bisphosphorylated and monophosphory- been identified as the minimal construct need to provide
lated forms of CDK7 produced by expression from bacu- activation of CDK7/cyclin H (Busso et al., 2000). How-
loviral vectors in insect cells but the crystal structure ever, the N-terminal RING finger domain is important for
contains only the monophosphorylated form in which transcription activation and promotion of phosphoryla-
Thr170 is phosphorylated. Evidently crystallization has tion of the CTD while the middle region comprising
selected the monophosphorylated form from the mix- a coiled-coil allows binding of CDK7/cyclin H/MAT1
ture. In contrast to pThr160CDK2 where the phosphory- through interactions with both XPD and XPB helicases
lated activation segment is disordered, CDK7 shows an (Busso et al., 2000). In contrast to CDK7 alone, further
ordered activation segment. The conformation of the phosphorylation of CDK7/cyclin H and CDK7/cyclin
activation segment is different from that of CDK2 and H/MAT228 by pCDK2/cyclin A led to an enhancement
from that of pCDK2/cyclin A but is closer to that of of activity against CDK2 substrate of 3.7-fold, sug-
gesting that phosphorylation on both Thr170 and Ser164the inactive CDK2. The CDK7 preparation prepared for
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al., 2001) explained why KAP will only dephosphorylate
pCDK2 when it is in its folded state and not when it is
denatured. There are changes in sequence in the KAP
recognition site of CDK2 in CDK7, which suggested that
this recognition site would be disrupted in CDK7. This
has been confirmed by the present work, which has
shown that CDK2 is a substrate for KAP but not CDK7.
We used site directed mutagenesis to change the L14
loop of CDK2 to resemble that of CDK7 (resulting in KM-
CDK2). The changes in sequence of just two amino acids
were sufficient to disrupt the recognition site and KAP
showed no activity against the KM-CDK2. In contrast
engineering the CDK2 sequence into the CDK7 L14 loop
(KM-CDK7) did not give a protein substrate for KAP. We
conclude that other factors, such as the greater rigidity
of the phospho-activation segment, could also contrib-
ute to the resistance of CDK7 to dephosphorylation by
KAP.
Protein kinases are major targets for drugs. There are
several compounds that are either on the market or in
advanced clinical trials for treatment of cancer, diabetes
and inflammatory diseases (Noble et al., 2004). One of
the major problems is to develop a compound that is
selective for a particular kinase or signaling pathway.
Almost all drugs developed so far target the ATP binding
site. We compared the ATP site in two homologous
kinases CDK2 and CDK7 to see if there are features that
might confer selectivity. The major differences between
CDK7 and CDK2 ATP sites occur at the “CDK2 Lys89Figure 7. KAP Activity against CDK2, KM-CDK2, CDK7, and KM-
CDK7 and Kinase Assays pocket” or “hydrophobic pocket” (Fabbro et al., 2002).
(A) KAP activity. Dephosphorylation of CDK2 is detectable by band- This pocket has been targeted successfully by CDK2
shift (lanes 1 and 2) but not for KM-CDK2 (lanes 3 and 4); no changes inhibitors (Davies et al., 2002; Davis et al., 2001; Gray
are detectable in the relative intensity of monophosphorylated and et al., 1998) to provide potent and selective inhibitors.
diphosphorylated CDK7 (lanes 5 and 6) or for KM-CDK7 (lanes 7 In CDK7 the residue corresponding to Lys89 at the bot-
and 8). The relative shift of bands between CDK7 and KM-CDK7 arise
tom of the pocket is Val100 (Figures 5B and 5C). Thisfrom the difference in phosphorylation state of CDK7 (discussed in
change together with other changes in the region suchtext).
(B) Comparison of kinase activities of CDK2 and CDK7 and their as Thr96 (in place of Gln85 in CDK2), and the presence
respective L14-loop mutants. CDK7 was used as substrate for of Pro310 creates a pocket of greater nonpolar character
CDK2; CTD was used as substrate for CDK7. (See text for further in CDK7 than in CDK2. In CDK4, Lys89 of CDK2 is re-
details.) placed by a threonine and this change has been ex-
ploited in the development of specific CDK4 inhibitors
are required for maximal activity. The change in sub- (Beattie et al., 2003; Breault et al., 2003; Honma et al.,
strate specificity conferred by MAT1, which shifts the 2001a, 2001b; Soni et al., 2001) and a CDK4-like mutant
preference to the CTD over CDK2, raises intriguing ques- of CDK2 (Ikuta et al., 2001). In CDK7 this hydrophobic
tions that can only be answered by structural studies on pocket offers the possibility for designing selective in-
the dimeric and trimeric complexes and their association hibitors.
with the substrates. The structure of CDK7 joins the structures of CDK2
Protein/protein interactions at sites remote from the (Brown et al., 1999a; De Bondt et al., 1993; Jeffrey et
catalytic site play key roles in many processes of protein al., 2001; Russo et al., 1996a), CDK5 (Tarricone et al.,
kinase substrate recognition (e.g., MAPK family; CDK2; 2001), and CDK6 (Brotherton et al., 1998; Russo et al.,
GSK; PLK1). The positions of these sites have been 1998; Schulze-Gahmen and Kim, 2002) as representa-
elucidated in a number of structural studies with pep- tive structures of the CDK family. Each of these exhibits
tides from the cognate substrate proteins (Bax et al., different regulatory and substrate specificity properties.
2001; Chang et al., 2002; Cheng et al., 2003; Dajani et For CDK7 further work is required to understand the
al., 2003; Elia et al., 2003; Lowe et al., 2002; Russo et activation by regulatory domains and to understand why
al., 1996b) and demonstrate that different parts of the CDK2 can phosphorylate CDK7 and CDK7 can phos-
kinase surface or regulatory domains may be involved phorylate CDK2 but neither can autophosphorylate. The
in such recognition. These studies have not yet shown role of additional protein recognition sites in these pro-
how the docking sites and the catalytic sites communi- cesses should provide a fascinating explanation of sub-
cate, if at all. The crystal structure of KAP in complex strate specificity as will understanding other processes
with pCDK2 represents one of the few examples where such as the interactions of cyclin H with the U1 snRNA
an enzyme in complex with its complete phospho-pro- that provide a link between transcription and RNA pro-
cessing (Kwek et al., 2002) and the interactions of CDK7tein substrate is known. The structural results (Song et
Structure
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Kinase Assayswith the Hepatitis C virus core protein that could link
CDK7, CDK7/cyclin H, and CDK7/cyclin H/MAT228 activities wereviral infection to cell cycle regulation (Ohkawa et al.,
measured by following the incorporation of radiolabeled phosphate2004).
into substrate. CDK2 (2.6	g 76 pmol) or GST-CTD (5	g 76pmol)
as substrates were incubated with 100 ng of CDK7, CDK7/cyclin H,
or CDK7/cyclin H/MAT228 in 10	l kinase buffer (0.1 mM ATP, 10 mMExperimental Procedures
MgCl2, 50 mM Tris-HCl (pH 7.5), 1 	Ci -32P-labeled ATP (Amersham
Biosciences). The reaction mixtures were incubated for 5 min atAll reagents, unless specified otherwise, were purchased from
20C and terminated by the addition of SDS sample buffer. Auto-Sigma-Aldrich (St. Louis, MO).
phosphorylated CDK7/cyclin H and CDK7/cyclin H/MAT228 were
obtained by incubating the each complex in 50 mM Tris-HCl (pH
7.5), 0.1 mM ATP, and 10 mM MgCl2 for 30 min at 20C. Fully phos-Expression, Purification, and Mass Spectrometry
phorylated CDK7, CDK7/cyclin H, and CDK7/cyclin H/MAT228 werepBS-CDK7 vector, kindly provided by Prof. David Morgan (Dept. of
obtained incubating each with 50 ng of pThr160-Cdk2/cyclin A inPhysiology, University of California, San Francisco, CA) and Prof.
50 mM Tris-HCl (pH 7.5), 0.1 mM ATP, and 10 mM MgCl2 for 30Robert P. Fisher (Memorial Sloan Kettering Cancer Center, New
min at 20C. Samples were analyzed on 12% SDS–PAGE gels andYork), was used as a template for the subsequent PCR. CDK7 was
exposed to the PhosphorImager image plate (Molecular Dynamics,cloned into the vector pVL1392 (Pharmingen BD, Franklin Lakes,
Amersham Biosciences). Pixels were quantified using the ImageJNJ) modified with the insertion of GST and PreScission protease
software (NIH) and converted into MBq using the equation: pixels cleavage site. CDK7-expressing baculovirus was obtained by
A ln(Mbq)  B. A and B are experimental parameters calculatedtransfecting 2 
 106 Sf21 cells with 2 	g of plasmid DNA and 0.5
from the image plate calibration. Data were normalized with respect	g of linearized baculovirus DNA for 5 days using BaculoGold Trans-
to the enzyme concentration.fection kit (Pharmingen BD). After two rounds of amplification,
expression was obtained by infecting Sf21 cells with GST-CDK7
KAP Assaybaculovirus (MOI 0.3) at 27C for 3 days. Cells were collected by
Dephosphorylation reactions were performed by incubating 0.5 	gcentrifugation at 1000rpm and resuspended in 50 mM Tris-HCl (pH
of pThr160-CDK2 or KM-pThr160-CDK2 with 0.2 	g of KAP or 2 	g8), 250 mM NaCl, 10% glycerol, and 10 mM DTT and Complete
of CDK7 or KM-CDK7 with 0.8 	g of KAP in 50 mM Tris (pH 7.5),protease inhibitor cocktail (Roche, Basel, Switzerland). Cells were
150 mM NaCl, 2 mM DTT, and 0.5 mM EDTA for 1 hr at roomdisrupted by sonication and the lysate, after clarification by centrifu-
temperature. Samples were then loaded on SDS-PAGE gel and ana-gation at 10,000 rpm, was loaded on GSH-Sepharose (Amersham
lyzed for bandshift by Coomassie blue stain.Biosciences, San Francisco, CA). Resin was washed with 10 column
volumes of the lysis buffer and then with 10 column volumes of 50
CrystallizationmM Tris-HCl (pH 8), 250 mM NaCl, 10% glycerol, 1 mM DTT, and
Sitting drop crystallization trials were performed at 4C using Molec-1 mM EDTA. Cleavage was performed overnight with 1 column volume
ular Dimensions (Soham, UK) Structure Screen I and II. Drops wereof the above buffer containing 40 	l of PreScission (Amersham
set up using Genesis ProTeam 150 crystallization robot (Tecan,Biosciences) protease/ml resin. Cleaved protein was recovered in
Reading, UK) and CrystalQuick 96-well plates (Greiner bio-one,2 column volumes of the same buffer and loaded onto Superdex
Longwood, FL) mixing 0.2 	l of CDK7 (7 mg/ml) with 0.2 	l of testing200 26/60 (Amersham Biosciences). Size-exclusion chromatogra-
solutions. Drops were equilibrated by vapor diffusion with 100 	l ofphy was run using 50 mM Tris-HCl (pH 8), 200 mM NaCl, 10%
its testing solution in the plate reservoir. Final crystallization condi-glycerol, and 1 mM DTT.
tions were identified as 0.1 M Na Citrate (pH 6.4), 0.2 M Na AcetateCyclin H baculovirus was a gift from Prof. David Morgan (Dept.
(pH 6.4), 20% PEG 4000, 10% glycerol, 200 mM nondetergent sul-of Physiology, University of California, San Francisco, CA). pGEX-
phobetaine 201 (NDSB201), and 2 mM ATP. The solubilizing agentMAT1, provided by Prof. Erich Nigg (Max Planck Institut, Martinsried,
NDSB201 helped prevent excessive nucleation and promoted crys-Germany), was used as a template for subsequent PCR. MAT228
tal growth. The crystals were transferred to 0.1 M Na Citrate (pH(corresponding to the C-terminal region of MAT1 residues 228–309)
6.4), 0.2 M Na Acetate (pH 6.4), 20% PEG 4000, 20% glycerol beforewas cloned into the vector pVL1392 (Pharmingen BD) modified with
freezing in liquid nitrogen.the insertion of MBP and PreScission protease cleavage site. CDK7/
cyclin H and CDK7/cyclin H/MAT228 complexes were produced by
coinfection of respective viruses in Sf21 cells. Purifications were X-Ray Data Collection, Data Processing,
and Structure Solutioncarried out as described above.
pGEX-CTD was provided by Dr. Andre Furger (Dept. of Biochemis- The crystals were small (50 
 10 
 5 	m). An initial dataset was
collected at beamline ID29, ESRF to 3.3 A˚ (Table 1.). The crystalstry, University of Oxford, UK) and used to transform DH5 cells. Cells
were induced overnight with 0.25 mM IPTG at 20C and sonicated in were space group P21 with four molecules per asymmetric unit. A
second data set was collected at the micro-focus beamline, ID1350 mM Tris-HCl (pH 8), 200 mM NaCl, 10% glycerol, and 10 mM
DTT and Complete protease inhibitor cocktail (Roche). Clarified ly- (ESRF) using a focal spot size of 10 	m . The high brightness of the
beam allowed data collection to 3 A˚ resolution (Table 1). However,sate was loaded on GSH-Sepharose (Amerham Biosciences) and
resin was then washed with 10 column volumes of lysis buffer and severe radiation damage allowed only 5–10 degrees of data to be
collected from one part of the crystal before it was necessary to10 column volumes of in 50 mM Tris-HCl (pH 8), 200 mM NaCl, 10%
glycerol, and 1 mM DTT. GST-CTD was then eluted with 2 column translate the crystal and continue data collection using an unex-
posed region. Each of these data segments was indexed separatelyvolumes of 50 mM Tris-HCl (pH 8), 200 mM NaCl, 10% glycerol, and
10 mM glutathione. with the program MOSFLM (Leslie, 1992). Only 80% overall com-
pleteness was achieved because of radiation damage. The 3 A˚ dataCDK2, pThr160-CDK2, and pThr160-CDK2/cyclin A were pro-
duced as previously described (Brown et al., 1999a) set was scaled together with the 3.3 A˚ dataset previously recorded.
The combined data set with addition of reflections in both the highpET28a-KAP expression vector was kindly provided by Prof. Da-
vid Barford (Institute of Cancer Research, London, UK) and subse- and low resolution shells resulted in data that gave a successful
structure solution.quently used to purify KAP as described (Hanlon and Barford, 1998).
Mutagenesis of pThr160-CDK2 and CDK7 to produce KAP interac- The structure was solved by molecular replacement with the pro-
gram MOLREP (CCP4, 1994) using a modified model of inactivetion mutants (KM) were performed using the Site Directed Mutagen-
esis Kit (Stratagene, La Jolla, CA, USA) and following manufacturer’s CDK2 (Protein Data Bank accession code 1HCK) as the search
object. MOLREP found three copies of the model (Rfactor  0.513,instructions. These mutants were expressed and purified adopting
the same procedures used for wild-type proteins. CC  0.294). Examination of the resulting electron density maps
revealed a further copy. A search in MOLREP using the previousMass spectrometric analyses were performed on VG Fisons “Plat-
form” single quadrupole mass spectrometer using samples desalted solution as fixed input and a search model corresponding to the
C-terminal domain of CDK2 (residues 104–152, 164–237, and 240–by drop dialysis.
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298) successfully identified the orientation of the fourth molecule CCP4 (Collaborative Computational Project Number 4) (1994). The
CCP4 suite: programs for protein crystallography. Acta Crystallogr.(Rfactor  50.5, CC  0.306). The difficulty in locating the fourth mole-
cule arose because of a clash between the second and fourth mole- D Biol. Crystallogr. 50, 760–763.
cules in the asymmetric unit in the region following the hinge corre- Chang, C.I., Xu, B.E., Akella, R., Cobb, M.H., and Goldsmith, E.J.
sponding to residues 97–100 of CDK2. This initially suggested that (2002). Crystal structures of MAP kinase p38 complexed to the dock-
there were two different conformations of CDK7 present within the ing sites on its nuclear substrate MEF2A and activator MKK3b. Mol.
asymmetric unit. However, upon rebuilding it became apparent that Cell 9, 1241–1249.
CDK7 differed from CDK2 in this region and the same backbone
Chen, J., Larochelle, S., Li, X., and Suter, B. (2003). Xpd/Ercc2 regu-
conformation was in fact present in all four copies. As a result, 4-fold
lates CAK activity and mitotic progression. Nature 424, 228–232.
averaging was applied to maps during rebuilding. Rebuilding was
Cheng, A., Kaldis, P., and Solomon, M.J. (2000). Dephosphorylationcarried out using O (Jones et al., 1991), followed by rounds of refine-
of human cyclin-dependent kinases by protein phosphatase typement in REFMAC5 (Murshudov et al., 1997) resulting in a final struc-
2C and 2 isoforms. J. Biol. Chem. 275, 34744–34749.ture with Rfactor  0.219, Rfree  0.296 (Table 1).
Cheng, K.-Y., Lowe, E.D., Sinclair, J., Nigg, E.A., and Johnson, L.N.
(2003). The crystal structure of the human polo-like kinase polo-Acknowledgments
box domain and its complex with a phosphopeptide. EMBO J. 22,
5757–5768.We wish to thank the scientists at ESRF for their help with data
collection, namely David Flot and Christian Riekel at ID13 and the Dahmus, M.E. (1996). Reversible phosphorylation of the C-terminal
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